The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...

The rollout of a vaccine for respiratory syncytial virus (RSV) has slashed hospital admissions by 30% among older people, ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

Abrysvo, which is now the first maternal RSV vaccine to be prequalified by the organisation, aims to prevent RSV-associated ...

Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...

New UKHSA study shows the RSV vaccination programme already achieving a 30% reduction in hospital admissions in older people in England as roll-out ...

Fresno County health officials have confirmed the first pediatric deaths linked to flu and RSV this season, urging ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ...

A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season.

Clover Biopharma receives IND clearance from US FDA and begins revaccination clinical study for RSV vaccine candidate SCB-1019: Shanghai Tuesday, March 25, 2025, 16:00 Hrs [IST] C ...

On 12 March 2025, the World Health Organization (WHO) prequalified the first maternal respiratory syncytial virus (RSV) vaccine to protect infants ...

Novavax reached a settlement with Gavi, the Vaccine Alliance, after t | International vaccine partnership Gavi has ...